As expected, mipomersen also resulted in significant reductions in app B, total cholesterol, and non-HDL cholesterol.

FORBES: FDA Review Raises Safety Concerns About Mipomersen

Torcetrapib does not seem to raise total cholesterol, as completely inhibiting CETP might.

FORBES: Magazine Article

The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

In December 2012, the FDA approved Juxtapid (lomitapide) to reduce LDL-C, total cholesterol, apolipoprotein B, and non HDL-C in patients with HoFH.

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

By using olive oil, you can decrease your total-cholesterol levels while maintaining your HDL levels, thus decreasing your risk for heart disease.

CNN: What's your cholesterol IQ?

Other fun facts like fat, saturated fat, cholesterol, sodium, total carbohydrates, sugars, fiber and total protein would have to be made available in writing upon request.

CNN: 10 lesser known effects of health care reform law

He also noted that labeling changes are not unusual, and that the other cholesterol drugs had undergone a combined total of 100 such labeling revisions since they were introduced.

FORBES: Crestor Warning A Boon For Astra--Or Pfizer?

Two new cholesterol drugs are entering the market, but some analysts say that even with the new entrants the total number of patients on impotence drugs is not increasing.

FORBES: Sex On Demand: A Big Disappointment